

























































Olaparib-Based Photoaffinity Probes for PARP-1 Detection
in Living Cells
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The poly-ADP-ribose polymerase (PARP) is a protein from the
family of ADP-ribosyltransferases that catalyzes polyadenosine
diphosphate ribose (ADPR) formation in order to attract the
DNA repair machinery to sites of DNA damage. The inhibition of
PARP activity by olaparib can cause cell death, which is of
clinical relevance in some tumor types. This demonstrates that
quantification of PARP activity in the context of living cells is of
great importance. In this work, we present the design, synthesis
and biological evaluation of photo-activatable affinity probes
inspired by the olaparib molecule that are equipped with a
diazirine for covalent attachment upon activation by UV light
and a ligation handle for the addition of a reporter group of
choice. SDS-PAGE, western blotting and label-free LC-MS/MS
quantification analysis show that the probes target the PARP-1
protein and are selectively outcompeted by olaparib; this
suggests that they bind in the same enzymatic pocket.
Proteomics data are available via ProteomeXchange with
identifier PXD018661.
One of the crucial steps in the repair of DNA double-strand
breaks is ADP-ribosylation of chromatin,[1–6] a process driven by
several members of the PARP family[7–9] otherwise known as
ARTDs (poly-ADP-ribosyltransferases).[10] This family of trans-
ferases represents clinically relevant target proteins for drugs
directed to tumors that are deficient in their DNA repair.[11,12]
The ability to monitor ARTDs in vivo is necessary if one wants to
study the processes of the drug-target engagement and
pharmacokinetics. Small molecule probes that are capable to
specifically and covalently bind to their target enzymes in living
cells and in tissues have been developed for various classes of
enzymes[13–17] and used in successful studies involving in vivo
protein detection and quantification. One way to attain such a
probe is to convert a known reversible enzyme inhibitor into a
covalent probe suitable for affinity-based protein profiling
(AfBPP).[17–20] AfBPP probes consist of a recognition element that
reversibly interacts with the target of interest on which a
photoreactive group and ligation handle are installed, without
affecting the affinity of the parent structure. Irradiation by UV
light activates the photoreactive group, forming a covalent
bond between the probe and the target protein in the process
called photo-affinity labeling (PAL).[19–22] The bioorthogonal
ligation handle is used to couple a reporter group, such as a
fluorophore for in-gel analysis or a biotin for affinity enrich-
ment, with subsequent tandem mass spectrometry in chemical
proteomics. In this work we present such a covalent probe for
the detection of PARP-1 in live cells using AfBPP (Figure 1). Prior
work on the detection of PARP was focused solely on non-
covalently binding molecules with the aim of either off-target
finding[23,24] or in vivo imaging[25,26] We set out to design,
synthesize and biologically validate a PARP-1-selective photo-
affinity probe for use in the standard proteomics protocols.
Such well-established workflows make use of UV-induced PAL
through a diazirine tag and copper-catalyzed alkyne-azide
cycloaddition that enable the pull-down of the protein for
subsequent analysis by standard mass-spectrometry methods.
The clinical PARP inhibitor olaparib was chosen as the
starting point for the design of the recognition element of
photoaffinity probes 3 and 6, because it inhibits PARP-1 and
PARP-2 with a nanomolar potency and shows exceptional
selectivity over other cellular targets[24,27,28] The synthesis of 3
and 6 is depicted in Scheme 1. For PAL, a plethora of photo
reactive groups is reported.[29] In order to limit the interference
of the tag with the activity and selectivity of the probes, we
chose the compact diazirine-alkyne linkers 2 and 5 developed
by Li et al.[30] The nitrogen atom of the piperazine moiety distal
from the phtalazinone substructure of olaparib is known to
tolerate a wide range of modifications.[28,31] With this in mind,
we attached the photoaffinity tag to this nitrogen to minimize
its influence on binding efficiency to PARP-1, giving the design
of probe 3. A second, simplified probe 6, in which we removed
the piperazine bridge and attached the diazirine-alkyne tag
directly to benzylphtalazinone core of the olaparib structure
was also synthesized. The probes were prepared by HCTU-
mediated condensation of either commercially available 1 or
known compound 4[25,28] with the linkers 2 and 5, respectively.
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With the AfBPs 3 and 6 in hand, their ability to bind PARP
covalently through PAL in live cells was tested on the human B-
cell-derived Raji cell line. Raji cells were chosen as the model
because they are easy to grow in suspension and have an
advantageous nucleus-to-cytoplasm ratio that maximizes the
PARP abundance. The cells were incubated with probes 3 or 6
(10 μM) and irradiated with UV light for 30 minutes to ensure
complete activation of the diazirine and covalent labeling of
PARP. During irradiation, the cells were cooled to 4 °C to
counteract the heat generated from the irradiation. The cells
were then harvested and lysed. The lysate was treated with the
azide-containing fluorophore AlexaFluor 647 under click con-
ditions and further processed for in-gel fluorescence analysis.
The gel revealed a fluorescent band at the expected height of
around 116 kDa (Figure 2, lanes 3) which was probe-dependent
as cells treated with only the DMSO vehicle (lanes 2) revealed
no labeling. The same cell lysates were also coupled to diazo
biotin-azide (DBA, Figure S4 in the Supporting Information) and
an anti-biotin western-blot (WB) revealed the same band at
116 kDa (Figure S1) verifying that the detected bands are
probe-specific. To further show probe-specific labeling, the UV
irradiation step was omitted yielding no signal, showing that
the observed labeling is UV-dependent rather than circum-
stantial activation. As an additional control, the gel used for in-
gel fluorescence readout was analyzed by western blot with an
anti-PARP-1 antibody showing bands at the same height
confirming it to be PARP-1 (Figure S1). To further verify our
target, we performed a click reaction with N-(3-azidopropyl)
biotinamide (Figure S5) on the lysates and enriched the probe-
Figure 1. Live Raji cells were treated with probe 3 or 6. Irradiation at 350 nm activates the diazirine group, forming a highly reactive carbene that can rapidly
insert into nearby N  H, O  H or C  H bonds. Protein extraction was done by cell lysis under denaturing conditions. Reporter or affinity handles were
introduced by CuAAC click chemistry. Proteins were analyzed by SDS-PAGE and/or western blot or by affinity purification, digested to peptides and LFQ
proteomics analysis.
Scheme 1. Structure of olaparib and the synthesis of the derived probes 3
and 6. a) HCTU, DIPEA, DMF, 33% for 3, 75% for 6.
Figure 2. SDS-PAGE analysis and fluorescent imaging of Raji cells exposed to
probes 3 and 6 (10 μM) without UV control. sim: simultaneous incubation at
a 1 :1 (10 μM olaparib, 10 μM probe) or 5 :1 (50 μM olaparib, 10 μM probe)
ratio. seq: sequential incubation with olaparib, wash and probe at 1 :1 ratio
or 2 :1 olaparib/probe ratio. FL: fluorescence channel. CBS: Coomassie Blue
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bound proteins on streptavidin beads. SDS-PAGE followed by
WB analysis with the anti-PARP-1 antibody proved the probe-
bound protein to be PARP-1 (Figure S2).
Having verified that probes 3 and 6 were able to label PARP
in a UV-dependent covalent manner, we reasoned they should
also be outcompeted by olaparib, as they should bind to the
same protein active site. The probes and olaparib were
incubated simultaneously in a 1 :1 ratio after which a decrease
of band intensity was observed (lanes 4). After increasing the
amount of olaparib to a 5 :1 drug/probe ratio, labeling by the
probe was fully diminished (lanes 5). Interestingly, in a
sequential competition experiment where first olaparib was
administered, removed and then incubated with the probes in
a 1 :1 ratio, no apparent competition was observed (lanes 7)
and when a 2 :1 drug/probe ratio was applied, the bands
appeared to decrease slightly (lanes 8) but proved not as
effective as simultaneous competition. This effect might be due
to rapid dissociation of olaparib from the PARP binding pocket
during the washing step.
Next, we wanted to show the probes ability to bind PARP in
conditions frequently encountered in the field of ADP-ribosyla-
tion research. H2O2 is often used to induce double strand
breaks, facilitating PARP activation. Therefore, Raji cells were
treated with the probes as before with addition of H2O2 during
incubation. The addition of this oxidizing agent neither
changed the ability of the probes to label PARP nor the
efficiency of the labeling (Figure S3).The latter result suggests
that olaparib is able to bind to PARP in the absence of extensive
DNA-damage and appears consistent with previously reported
findings.[23]
To identify and quantify the bands seen by SDS-PAGE and
western blot analysis we used a LC-MS/MS-based label-free
quantification (LFQ) method.[16] The results show that PARP-1 is
significantly UV-enriched by probe 3, thus indicating that the
observed band at 116 kDa can be attributed to PARP-1
(Figure 3A and B). Competition analysis of significantly UV-
enriched proteins shows that PARP-1 is outcompeted by
olaparib (Figure 3D); this strongly indicates that the probe binds
in the same protein pocket as olaparib. Several other proteins
were selectively enriched by the probe upon UV irradiation
having a nucleic acid binding motif as common feature,
indicating that the probe targets these proteins possibly by
their nucleic acid binding or perhaps by the presence of the
diazirine group (Figure 3C).[33] PARP-1 was not significantly UV
enriched by probe 6 (Figure S6), which agrees with the in-gel
fluorescence data for this probe that showed fainter bands for
PARP-1 compared with the background. Apparently, removal of
the piperazine ring diminishes the binding affinity of probe 6 to
PARP-1.
In conclusion, we present for the design and synthesis of
two synthetically accessible olaparib-based photoaffinity probes
(3 and 6) for PARP-1 detection in living cells. We show evidence
Figure 3. LFQ proteomics analysis of probe 3 in living Raji cells of proteins with at least two unique peptides. A) Waterfall plot of UV enrichment by probe 3 of
proteins identified in the proteomics analysis, proteins showing a more than threefold UV enrichment are in black. B) Volcano plot of UV enrichment of
proteins by probe 3, proteins showing a more than threefold UV enrichment and with p<0.05 using a Student’s t-test are in black. PARP-1 is marked in red. C)
Significantly UV-enriched proteins sorted with the gene function analysis module of the PANTHER classification system (v.14.0) software.[32] D) Competition
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of efficacy and provide a detailed protocol for application of
these probes. Both 3 and 6 proved to be stable under oxidative
conditions often employed for PARP activation while probe 3
was successfully used to label PARP-1 selectively in a live-cell
model and to analyze its presence by in-gel fluorescence and
LFQ LC-MS/MS methods.
The mass spectrometry proteomics data have been depos-
ited with the ProteomeXchange Consortium via the PRIDE[35]
partner repository with the dataset identifier PXD018661.
Note added in proof
While this paper was under review, a similar approach for PARP-
targeting was published by Tate and co-workers.[34]
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Impair the repair: Olaparib is a PARP
inhibitor (PARPi) of clinical relevance
because it causes cell death in
certain tumor types. By using a sub-
structure of olaparib and adding a
photo-activatable linker, a proteo-
mics assay is presented for visualiz-
ing PARP1 with in-gel fluorescence
and MS/MS analysis.
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